Corporate Banner
Satellite Banner
ADME Tox
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Researchers Identify Novel Class of Drugs for Prostate Cancers

Published: Wednesday, May 29, 2013
Last Updated: Wednesday, May 29, 2013
Bookmark and Share
A new study on prostate cancer describes a novel class of drugs that interrupts critical signaling needed for prostate cancer cells to grow.

In men with advanced prostate cancer, growth of cancer cells depends on androgen receptor signaling, which is driven by androgens, such as testosterone. To thwart tumor growth, most patients with advanced prostate cancer receive drugs that block the production of androgen or block the receptor where the androgen binds. Unfortunately, such treatments invariably fail and patients die of prostate cancer with their androgen receptor signaling still active and still promoting tumor growth.

In the new study, available online at Nature Communications, a team of researchers led by Dr. Ganesh Raj, associate professor of urology at UT Southwestern, found that they could disrupt androgen receptor signaling using a novel class of drugs called peptidomimetics. This therapeutic agent consists of an engineered small protein-like chain designed to mimic peptides that are critical for androgen receptor function. The peptidomimetic agents block the activity of the androgen receptor even in the presence of androgen by attacking the protein in a different spot from where the androgen binds.

“We are hopeful that this novel class of drugs will shut down androgen receptor signaling and lead to added options and increased longevity for men with advanced prostate cancer,” said Dr. Raj, the senior author of the study.

Dr. Raj compared the action that takes place to a lock and key mechanism. In prostate cancer, the androgen receptor (lock) is activated by the androgen (key) resulting in a signal that causes prostate cancer proliferation. In advanced prostate cancer, despite drugs targeting either the lock (androgen receptor) or the key (androgen production), there can be aberrant keys that open the lock or mutated locks that are always open, resulting in cancer cell proliferation. Instead of trying to block the lock or the key, peptidomimetics uncouple the lock and key mechanism from the proliferation signal. Thus, even with the androgen receptor activated, the prostate cancer cells do not receive the signal to proliferate and do not grow.

The researchers tested their drug in mouse and human tissue models. The novel drug proved non-toxic and prevented androgen receptor signaling in cancer cells. The response is highly promising and suggests that peptidomimetic targeting of prostate cancer may be a viable therapeutic approach for men with advanced disease.

Further testing is needed before a drug could move to Phase 1 clinical trials that involve human participants.

“Most drugs now available to treat advanced prostate cancer improve survival rates by three or four months,” Dr. Raj said. “Our new agents may offer hope for men who fail with the current drugs.”

These findings represent the development of a first-in-class agent targeting critical interactions between proteins. Other cellular and disease processes eventually could also be targeted with peptidomimetics, the scientists said.

Other UT Southwestern researchers involved in the study are Preethi Ravindranathan, a technician in Dr. Raj’s laboratory, Dr. Jer-Tsong Hsieh, professor of urology, and Dr. Jung-Mo Ahn, visiting associate professor of urology. Researchers from University of Texas at Dallas; the First Affiliated Hospital of Medical College of Xi’an Jiaotong University, Urology Institute of Xi’an Jiaotong University; Dame Roma Mitchell Cancer Research Laboratories and Adelaide Prostate Cancer, Research Center, University of Adelaide and Hanson Institute also contributed to the research.

The Prostate Cancer Foundation, the Dorothy and James Cleo Thompson Foundation, and the Robert A. Welch Foundation funded the research.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,400+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

UT Southwestern Research Suggests New Way to Ensure Effectiveness of TB Treatment
By using a “glass mouse” research model study founds that multidrug-resistant TB is caused in patients by speedy drug metabolism.
Friday, January 20, 2012
Anemia Drug Not Helpful for Kidney Disease Patients, UT Southwestern Researcher Reports
Study concluds that the anemia drug darbepoetin alfa works no better than a placebo in several applications previously thought to be promising.
Thursday, December 24, 2009
Higher Drug Doses Needed to Defeat Tuberculosis, UT Southwestern Researchers Report
The typical dose of a medication considered pivotal in treating tuberculosis effectively is much too low to account for modern-day physiques, researchers say.
Monday, August 03, 2009
UT Southwestern Researchers Probe Kidney Damage, Protection in Lupus
Researchers also found that a certain set of genes appears to protect the kidneys from a different sort of immune attack.
Monday, April 27, 2009
UT Southwestern Researchers Find Clue to Safer Obesity Drugs
Scientists are trying to understand how a miracle weight-loss drug behaves in the brain in order to develop safer anti-obesity drugs with fewer side effects.
Wednesday, November 26, 2008
UT Southwestern Scientists Discover Leptin can Also Aid Type 1 Diabetics
Terminally ill rodents with type 1 diabetes have been restored to full health with a single injection of a substance other than insulin by the scientists.
Tuesday, August 26, 2008
Researchers uncover molecule that keeps pathogens like salmonella in check
Scientists at UT Southwestern Medical Center have found a potential new way to stop the bacteria that cause gastroenteritis, tularemia and severe diarrhea from making people sick.
Tuesday, August 26, 2008
Pros, Cons of Drug Proven to Prevent Prostate Cancer should be Considered, UT Southwestern Researchers Recommend
Findings encourage men to weigh both the potential benefits and side effects of the drug finasteride before taking it to prevent prostate cancer.
Tuesday, January 22, 2008
Scientific News
RNAi Screening Trends
Understand current trends and learn which application areas are expected to gain in popularity over the next few years.
Long-sought Discovery Fills in Missing Details of Cell 'Switchboard'
A biomedical breakthrough reveals never-before-seen details of the human body’s cellular switchboard that regulates sensory and hormonal responses.
Tracking Breast Cancer Before it Grows
A team of scientists led by University of Saskatchewan researcher Saroj Kumar is using cutting-edge Canadian Light Source techniques to screen and treat breast cancer at its earliest changes.
Zebrafish Reveal Drugs that may Improve Bone Marrow Transplant
Compounds boost stem cell engraftment; could allow more matches for patients with cancer and blood diseases.
Teeth Reveal Lifetime Exposures to Metals, Toxins
Researchers have identified dental biomarkers to reveal links between early iron exposure and late life brain diseases.
An Innovative Algorithm to Decipher How Drugs Work Inside the Body
Researchers at Columbia University Medical Center (CUMC) have developed a computer algorithm that is helping scientists see how drugs produce pharmacological effects inside the body.
Uncovering the Spread of Bacteria in Pneumonia
Northwestern Medicine scientists have discovered the role a toxin produced by a pneumonia-causing bacterium plays in the spread of infection from the lungs to the bloodstream in hospitalized patients.
Ferring Bets on Bacteriophages to Treat Inflammatory Bowel Disease
Ferring Pharmaceuticals have annoucned that it will collaborate with Intralytix in the latest phase of its early stage development programme for a bacteriophage-based therapy for inflammatory bowel disease (IBD).
Rare Form: Novel Structures Built from DNA Emerge
DNA, the molecular foundation of life, has new tricks up its sleeve. The four bases from which it is composed can be artificially manipulated to construct endlessly varied forms in two and three dimensions.
Early Lead Exposure Has Long Lasting Effect
A team of researchers have found links between lead exposure in children and epigenetic alterations in regulatory regions of genes that are imprinted and known to be critical in growth regulation and brain development.
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,400+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!